Verdict

What's Next

Hold at ₹449: probability-weighted value ₹456 (+1.6%), asymmetry 1.1x, suggested size 0.5% to 1.0% until cash conversion improves.

The next hard catalyst is FY2026 audited results, expected in late May 2026 based on prior audited-result board dates (May 23, 2024 and May 23, 2025). No separate analyst consensus file was available in this run, so market expectations are inferred from reported run-rate.

No Results

No Results

The setup is catalyst-light after the May print unless the company gives a concrete operational update. If May results do not show meaningful cash-flow repair, valuation can stay optically cheap but range-bound.

The Verdict

Current Price (₹)

449

Probability-Weighted Value (₹)

456

PW Upside

1.6%

Asymmetry (Upside/Downside)

1.2

Suggested Position (%)

0.8

Verdict: Hold (Conviction /10)

4.5

No Results

Bull case (25%, ₹650): FY2026 audited numbers confirm PAT scale-up and, critically, cash conversion improves toward CFO/OP above 40% with debtor days trending down from FY2025 stress levels. That combination can support a higher quality multiple even without immediate mainboard migration.

Base case (50%, ₹460): earnings remain strong but cash normalization is only partial, so valuation remains constrained by execution credibility and receivable risk. This is the most likely path over the next two result cycles.

Bear case (25%, ₹255): cash flow stays weak despite reported profit growth, receivables remain elevated, and India ramp evidence is delayed again. In this path, the stock de-rates as a concentrated, cash-uncertain SME story.

The probability math is explicit: (₹650 × 25%) + (₹460 × 50%) + (₹255 × 25%) = ₹456. Versus ₹449, that is only +1.6% expected value, so there is no strong edge right now.

No Results

What the market may be missing is not just low valuation, but the convexity if India growth comes with cleaner collections than the Uganda-heavy base. What the market is likely correctly discounting is that this proof has not arrived yet in audited cash flow.

LEAPS / Options

No Results

No actionable options setup: this run has no options chain file for UNIHEALTH, and the stock trades on NSE SME where derivatives liquidity is typically absent.

Claude View

The Verdict

Conditional Buy at ₹449 – probability-weighted value ₹530, 18% upside, but only for investors who can tolerate SME illiquidity and accept that 74% of profits come from a single Ugandan hospital. Position size: 1-2% of portfolio. The H1 FY26 earnings explosion (₹29 Cr PAT vs ₹15 Cr full-year FY25) has collapsed the forward P/E to ~10x on TTM earnings – genuinely cheap for a 75%+ profit growth business – but 328 debtor days and negative operating cash flow mean you are buying an accounting profit stream, not a cash flow stream.

CMP (₹)

449

PW Value (₹)

530

TTM P/E

9.9

Asymmetry Ratio

1.6

Market Cap (₹ Cr)

705

TTM PAT (₹ Cr)

PW Upside

18%

**The call:** Conditional Buy at ₹449. The stock is cheap on TTM earnings (10x P/E vs 50-90x for listed hospital peers), but the cheapness reflects real risks -- SME illiquidity, Uganda concentration, and unproven India execution. Buy only if you believe Nashik commissioning will succeed and receivables will normalize. Size small (1-2%). No options available on NSE SME stocks.

What's Next

No Results

FY2026 full-year results (May 2026) are the next major event. Based on H1 FY26 (₹67 Cr revenue, ₹29 Cr PAT at 48% OPM), the market expects FY26 revenue of ₹120-140 Cr and PAT of ₹45-55 Cr. The key question is whether H2 FY26 sustained H1's margin momentum or whether the 48% OPM was a one-off benefiting from Uganda's new 10-year tax holiday (effective July 2024) and super-specialty ARPOB uplift.

Nashik 200-bed commissioning is the single most important catalyst in the next 6 months. Originally promised for December 2025, then pushed to January-February 2026, the hospital is expected to be operational by now. The first occupancy data from Nashik will be visible in Q1 FY27 results. If Nashik reaches 30%+ occupancy within the first two quarters, the India thesis gains credibility. If it remains below 20%, the market will question whether this micro-cap can build a brand in Maharashtra.

The warrant conversion on April 10, 2026 (2 lakh shares at ₹151, well below the ₹449 market price) is minor dilution (~1.3%) but signals insider confidence – someone exercised warrants at a 66% discount to market.

Mainboard migration remains speculative but would be the most powerful re-rating catalyst. An NSE mainboard listing would trigger enhanced disclosure, institutional eligibility, and potential index inclusion. The company's ₹705 Cr market cap and improving financials make it increasingly eligible, but no formal application has been announced.

What the market is watching most closely: Cash flow normalization. Two consecutive periods of negative operating cash flow (FY25 and H1 FY26) despite surging profits is the single biggest skepticism point. If FY26 audited results show positive OCF, the narrative shifts from "accounting profits" to "real earnings."

The Verdict

Scenario Analysis

**Bull Case (25% probability) -- Target ₹750:** Nashik reaches 40%+ occupancy within 12 months. FY27 revenue hits ₹200 Cr with 30%+ EBITDA margins. Receivables normalize to 200 days as India revenue (insurance-paid, faster collection) dilutes Uganda's long-cycle government receivables. Stock re-rates to 15x forward earnings on ₹50 Cr FY27 PAT = ₹750. Math: ₹50 Cr PAT x 15x P/E / 1.57 Cr shares = ₹478 per share ... but with mainboard migration optionality and continued growth, 18-20x is plausible = ₹636-680. Rounding to ₹750 assumes partial multiple re-rating toward the cheapest listed peer (Medanta at 50x).

**Base Case (50% probability) -- Target ₹500:** FY26 delivers ₹130 Cr revenue, ₹45 Cr PAT. Nashik commissions but ramps slowly (20-30% occupancy in year one). Blended margins compress to 30-33% as India beds dilute Africa margins. Receivables remain elevated at 280-300 days. Stock trades at 11-12x forward FY27 earnings of ₹42 Cr = ₹480-530. Midpoint ₹500. The company executes at 70% of its promises -- good enough to hold value, not enough to re-rate.

**Bear Case (25% probability) -- Target ₹250:** Nashik fails to attract patients (below 15% occupancy after 12 months). Uganda receivables from the Ministry of Defense become impaired or collection stretches to 18+ months. FY27 PAT stalls at ₹30 Cr as India losses offset Uganda gains. The market re-prices this as a single-hospital African operator at 8x earnings = ₹240. Additional risk: UGX depreciation, political instability in Uganda, or promoter credibility loss from continued timeline misses.

Probability-Weighted Value

No Results

Probability-weighted value: ₹530 vs CMP ₹449 = 18% upside.

Asymmetry ratio: Bull upside ₹301 (₹750 - ₹449) x 25% = ₹75 weighted upside. Bear downside ₹199 (₹449 - ₹250) x 25% = ₹50 weighted downside. Asymmetry: 1.6x – modestly favorable but not compelling enough for aggressive sizing.

Conditions for Success

No Results

Failure Triggers

No Results

What the Market May Be Missing

The market is pricing Unihealth at a TTM P/E of ~10x – a massive discount to the hospital sector (50-90x). Two things could explain whether this discount is an opportunity or a trap.

What the market may undervalue: The Uganda tax holiday (10 years from July 2024) is a genuine structural tailwind that is not widely understood. It pushed H1 FY26 tax rate to just 4% vs 29% in H1 FY25. On a ₹120+ Cr revenue base, this tax shield alone adds ₹8-12 Cr of annual PAT that would not exist otherwise. Combined with the super-specialty ARPOB uplift (₹25K to ₹40K+), the Uganda unit is a meaningfully better business than it was 18 months ago – and the stock price only partially reflects this.

What the market is correctly discounting: The cash flow problem is real and structural, not cyclical. A hospital that takes 11 months to collect from its single largest payer (Uganda Ministry of Defense, ₹82 Cr outstanding) cannot fund growth internally. Every new bed in India requires external capital. The 1,000-bed ambition on a ₹56 Cr (FY25) revenue base and negative free cash flow is aspirational – the company will either need to raise equity (dilutive) or take on debt (currently low at 0.13x D/E, so there is capacity). The SME listing illiquidity (1,058 shareholders, no institutional presence) means there is no floor under the stock if sentiment turns.

Position Sizing

No Results

1-2% of portfolio, maximum. The asymmetry is modestly favorable (1.6x) but path risk is elevated: this is an SME stock with 1,058 shareholders, no institutional ownership, and daily volumes that can evaporate. A 10% position would be reckless; even 3% introduces concentration risk in a name where a single bad quarter could gap the stock down 30-40% with no bid.

Entry discipline: Accumulate below ₹450. Add on dips toward ₹380-400 (base case P/E of ~9x on TTM). Do not chase above ₹480.

Exit triggers: Sell if any two failure triggers materialize simultaneously. Take partial profits at ₹600+ (bull case entry zone). Full exit above ₹700 unless FY27 earnings clearly support higher multiples.

No options available. This is an NSE SME stock with no derivatives listing. The only way to express a view is through equity. This limits the ability to define risk – you cannot buy puts for protection or sell calls for income. Position sizing is therefore your only risk management tool.